Search Result

Results for "

EGFR-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (5) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (31) Autophagy (2) Bacterial (1) Bcl-2 Family (7) Btk (1) c-Met/HGFR (3) CaMK (1) Caspase (7) CD44 (1) CDK (14) COX (6) Dihydrofolate reductase (DHFR) (2) Drug Isomer (2) Drug Metabolite (1) EGFR (104) ERK (4) FAK (1) FGFR (1) GSK-3 (1) HSP (1) IGF-1R (1) IKK (1) Isotope-Labeled Compounds (2) LYTACs (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) Microtubule/Tubulin (2) mRNA (1) Necroptosis (1) p38 MAPK (2) PARP (1) PDGFR (4) PROTACs (1) Reference Standards (9) SOS1 (1) SphK (1) Src (1) Survivin (1) Thymidylate Synthase (2) Topoisomerase (4) Trk Receptor (1) VEGFR (24)
By Research Areas:	Cancer (109) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (5)
Click Chemistry:	Azide (1) Alkynes (1)
Oligonucleotides:	mRNA (1)

115

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13272

Dacomitinib Maximum Cited Publications 29 Publications Verification PF-00299804; PF-299804	EGFR Apoptosis	Cancer
Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for *EGFR, ERBB2*, and ERBB4, respectively .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of *EGFR, HER2*, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-104065

Pyrotinib 15+ Cited Publications SHR-1258	EGFR	Cancer
Pyrotinib (SHR-1258) is a potent and selective *EGFR/HER2* dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-135815

Mobocertinib 10+ Cited Publications TAK-788; AP32788	EGFR	Cancer
Mobocertinib (TAK-788) is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type *EGFR*. Mobocertinib can be used in NSCLC research ^[2].

HY-164718

Sevabertinib BAY 2927088	EGFR	Cancer
Sevabertinib (BAY 2927088) is an orally active and reversible dual *EGFR-HER2* inhibitor (IC ⁵⁰ <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer ^[2].

HY-136789

Tuxobertinib 1 Publications Verification BDTX-189	EGFR	Cancer
Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric *EGFR* and *HER2* oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .

HY-13050

Sapitinib 15+ Cited Publications AZD-8931	EGFR	Cancer
Sapitinib (AZD-8931) is a reversible, ATP competitive *EGFR* inhibitor of with IC₅₀s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.

HY-10333

BMS-690514 2 Publications Verification	EGFR VEGFR	Cardiovascular Disease Cancer
BMS-690514 is a potent and orally active inhibitor of *EGFR* and VEGFR; has IC₅₀s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.

HY-10261B

(E/Z)-Afatinib (E/Z)-BIBW 2992	EGFR Apoptosis c-Met/HGFR Akt p38 MAPK Autophagy	Others Cancer
(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .

HY-18609

PD158780 4 Publications Verification	EGFR	Cancer
PD158780 is a potent *EGFR* family inhibitor with IC₅₀s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.

HY-17632

Tarloxotinib bromide 1 Publications Verification TH-4000	EGFR	Cancer
Tarloxotinib bromide (TH-4000) is an irreversible *EGFR/HER2* inhibitor.

HY-104065B

Pyrotinib dimaleate 15+ Cited Publications SHR-1258 dimaleate	EGFR	Cancer
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective *EGFR/HER2* dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-135815A

Mobocertinib succinate 10+ Cited Publications TAK-788 succINate; AP32788 succINate	EGFR	Cancer
Mobocertinib (TAK-788) succinate is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type *EGFR*. Mobocertinib succinate can be used in NSCLC research ^[2].

HY-101042

AG-494 TyrphostIN AG 494	EGFR CDK	Cancer
AG-494 (Tyrphostin AG 494) is a potent and selective *EGFR* tyrosine kinase inhibitor (IC₅₀=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC₅₀s 1.1, 39, 45 and 6 μM, respectively. AG-494 blocks Cdk2 activation and inhibits EGF-dependent DNA synthesis ^[2] .

HY-144304

PROTAC EGFR degrader 2	PROTACs EGFR	Cancer
PROTAC EGFR degrader 2 is a potent PROTAC *EGFR* degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC₅₀ of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM. PROTAC EGFR degrader 2 can be used for the synthesis of nitroreductase (NTR)-responsive PROTAC .

HY-15732

BGB-102 JNJ-26483327	EGFR	Cancer
BGB-102 is a potent multi-kinase inhibitor against *EGFR, HER2*, and HER4 with IC₅₀s of 9.6 nM, 18 nM and 40.3 nM, respectively.

HY-103440

EGFR/ErbB-2/ErbB-4 inhibitor-3	EGFR	Cancer
EGFR/ErbB-2/ErbB-4 inhibitor-3 (compound 29) is a potent tyrosine kinase inhibitor with IC₅₀s of 0.3, 1.1, 0.5, 2.5, 24 nM for erbB1, erbB2, erbB4, EGF, HER, respectively . EGFR/ErbB-2/ErbB-4 inhibitor-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-119016

SK1-I 1 Publications Verification BML-258	SphK CaMK	Cancer
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of 10 μM . SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity ^[2].

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC₅₀s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .

HY-100520

*EGFR-IN-2*	EGFR	Cancer
EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation *EGFR* inhibitor.

HY-100499

Tyrphostin AG 528 1 Publications Verification TyrphostIN B66; AG 528	EGFR	Cancer
Tyrphostin AG 528 is an inhibitor of *EGFR* and *ErbB2* with IC₅₀s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC₅₀s of 4.9 μM for epidermal growth factor receptors (EGFR) and 2.1 μM for *ErbB2* . Tyrphostin AG 528 is also an anticancer agent ^[2].

HY-175809

SRT6	CD44 Src EGFR MAPKAPK2 (MK2)	Cancer
SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44 ⁺ breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as *EGFR, ERBB2*, ERBB4, MAP3K10 and *MAPKAPK2*. SRT6 can be used for the research of breast cancer and lung cancer .

HY-146228

HSP90-IN-13	HSP Apoptosis Topoisomerase EGFR VEGFR	Cancer
HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .

HY-128860

Mutated EGFR-IN-2	EGFR	Cancer
Mutated EGFR-IN-2 (compound 91) is a mutant-selective *EGFR* inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC₅₀=＜1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity .

HY-151573

EGFR/CDK2-IN-1	EGFR CDK	Cancer
EGFR/CDK2-IN-1 (Compound 3b) is an *EGFR/CDK2* inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .

HY-174414

EGFR/HER2-IN-18	EGFR	Cancer
EGFR/HER2-IN-18 is a stable *EGFR/HER2* dual inhibitor with IC₅₀ values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer .

HY-178942

EGFR/VEGFR2-IN-9	VEGFR EGFR Apoptosis Bcl-2 Family Caspase MDM-2/p53	Cancer
EGFR/VEGFR2-IN-9 (Compound 9b) is an inhibitor of *VEGFR-2* (IC₅₀ = 1.325 μM) and *EGFR* (IC₅₀ = 1.891 μM). EGFR/VEGFR2-IN-9 significantly inhibits the proliferation of multiple cancer cell lines, particularly leukemia cells. EGFR/VEGFR2-IN-9 upregulates the expression levels of Bax, caspase-3, and p53, while downregulating the expression of *Bcl-2. EGFR/VEGFR2-IN-9* induces apoptosis and arrests the cell cycle in the G1 phase. EGFR/VEGFR2-IN-9 can be used to investigate anti-tumor angiogenesis and multi-drug resistant cancers .

HY-112420

EGFR/ErbB-2-IN-2	EGFR	Infection Metabolic Disease Cancer
EGFR/ErbB-2-IN-2 is a *EGFR* and ErbB inhibitor with IC₅₀s of 0.017 μM, 0.08 μM, 1.91 μM for EGFR, ErbB-2 and ErbB-4 .

HY-178440

EGFR/COX-2-IN-2	EGFR COX Apoptosis	Inflammation/Immunology Cancer
EGFR/COX-2-IN-2 (Compound 10a) is a dual inhibitor targeting epidermal growth factor receptor (EGFR) (IC₅₀= 6.0 μM) and cyclooxygenase-2 (COX-2) (IC₅₀=50 μM). EGFR/COX-2-IN-2 induces S-phase cell cycle arrest and apoptosis. EGFR/COX-2-IN-2 is promising for research of cancers and inflammation-related diseases .

HY-150905

*EGFR ligand-2*	EGFR	Cancer
EGFR ligand-2 (compound C4), a covalent *EGFR* ligand, is a EGFR mutant inhibitor with IC₅₀s of 21 nM and 48 nM for EGFR ^L858R and EGFR ^L858R/T790M, respectively. EGFR ligand-2 can be used to synthesize PROTAC .

HY-104065A

(Rac)-Pyrotinib (Rac)-SHR-1258	Drug Isomer	Cancer
(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemic form of Pyrotinib (HY-104065). Pyrotinib is a potent and selective dual EGFR/HER2 receptor inhibitor.

HY-13272R

Dacomitinib (Standard) PF-00299804 (Standard); PF-299804 (Standard)	Reference Standards EGFR Apoptosis	Cancer
Dacomitinib (Standard) is the analytical standard of Dacomitinib. This product is intended for research and analytical applications. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for *EGFR, ERBB2*, and ERBB4, respectively .

HY-161141

EGFR/c-Met-IN-2	c-Met/HGFR	Cancer
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of *EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M* phase. EGFR/c-Met-IN-2 has antitumor activity .

HY-155227A

ALK/EGFR-IN-2	Anaplastic lymphoma kinase (ALK)	Cancer
ALK/EGFR-IN-2 is a potent dual inhibitor of ALK and *EGFR*. ALK/EGFR-IN-2 induces apoptosis and G0/G1 cell cycle arrest in cancer cells. ALK/EGFR-IN-2 significantly inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC₅₀s of 0.0034, 0.0065, and 0.0018 μM, respectively .

HY-168514

SOS1/EGFR-IN-2	SOS1 EGFR	Cancer
SOS1/EGFR-IN-2 (Compound 4) is a SOS1 and *EGFR* dual inhibitor with IC₅₀s of 8.3 and 14.6 nM, respectively. SOS1/EGFR-IN-2 exhibits significant antiproliferative effect on the cancer cells haboring various KRAS mutants .

HY-162623

EGFR/HER2-IN-15	EGFR	Cancer
EGFR/HER2-IN-15, a dihydropyrimidine, is a potent *EGFR/HER2* inhibitor. EGFR/HER2-IN-15 significantly inhibits EGFR ^wt activity with an IC₅₀ of 37.21 nM. EGFR/HER2-IN-15 has anticaner effects .

HY-146238

EGFR/HER2/TS-IN-1	EGFR Thymidylate Synthase Apoptosis	Cancer
EGFR/HER2/TS-IN-1 (Compound 4d) is an *EGFR, HER2* and TS (Thymidylate synthase) inhibitor with IC₅₀ values of 0.203, 0.088 and 0.168 μM against EGFR, HER2 and TS, respectively. EGFR/HER2/TS-IN-1 induces MCF7 cell apoptosis .

HY-161602

EGFR/HER2-IN-13	EGFR	Cancer
EGFR/HER2-IN-13 (Compd 38) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-13 can be used for cancer research .

HY-161603

EGFR/HER2-IN-14	EGFR	Cancer
EGFR/HER2-IN-14 (Compd 46) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-14 can be used for cancer research .

HY-179031

EGFR/VEGFR2-IN-7	EGFR VEGFR Apoptosis	Cancer
EGFR/VEGFR2-IN-7 (Compound 3e) is a dual-target *EGFR/VEGFR2* inhibitor, with IC₅₀ values of 142 (EGFR) and 71 nM (VEGFR2). EGFR/VEGFR2-IN-7 exhibits broad-spectrum and potent anti-proliferative activity, especially being sensitive to breast cancer. EGFR/VEGFR2-IN-7 induces cell cycle arrest and apoptosis, inhibits cell migration and invasion. EGFR/VEGFR2-IN-7 can be used for research on breast cancer .

HY-151156

EGFR/HER2-IN-6	EGFR Apoptosis	Cancer
EGFR/HER2-IN-6 (compound 43) is an *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-6 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.122, 0.078 and 0.585 μM, respectively. EGFR/HER2-IN-6 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

HY-151161

EGFR/HER2-IN-8	EGFR	Cancer
EGFR/HER2-IN-8 (compound 34) is a *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

HY-168073

EGFR/VEGFR2-IN-1	EGFR VEGFR Apoptosis Microtubule/Tubulin	Cancer
EGFR/VEGFR2-IN-1 (Compound 10e) is a *VEGFR-2* and *EGFR* inhibitor (IC₅₀: 0.26 and 0.14 μM respectively). EGFR/VEGFR2-IN-1 inhibits tubulin polymerization with an IC₅₀ of 40.9 μM. EGFR/VEGFR2-IN-1 induces apoptosis. EGFR/VEGFR2-IN-1 can be used for research of antileukemia and antilymphoma .

HY-168655

EGFR/VEGFR2-IN-3	Apoptosis EGFR VEGFR	Cancer
EGFR/VEGFR2-IN-3 (compound 9) is a potent *EGFR* and *VEGFR-2* inhibitor with IC₅₀ values of 0.129, 0.142, 3.428 µM for EGFR, VEGFR-2, COX-2, respectively. EGFR/VEGFR2-IN-3 shows cytotoxicity. EGFR/VEGFR2-IN-3 induces apoptosis and cell cycle arrest at G2/M phase .

HY-170932

EGFR/COX-2-IN-1	EGFR COX Apoptosis	Cancer
EGFR/COX-2-IN-1 is an *EGFR/COX-2* inhibitor. EGFR/COX-2-IN-1 inhibits EGFR ^WT, EGFR ^T790M, COX-1 and *COX-2* with IC₅₀s of 0.12, 0.076, 20.1 and 1.52 μM respectively. EGFR/COX-2-IN-1 inhibits and with IC₅₀s of , respectively. EGFR/COX-2-IN-1 inhibits MCF-7, HT-29 and A-549 with IC₅₀s of 1.20, 5.14 and 14.81 μM, respectively. EGFR/COX-2-IN-1 displays Apoptosis induction by up-regulating Bax and down-regulating *Bcl-2* protein levels. EGFR/COX-2-IN-1 results in a significant increase in the percentage of cells at the G2/M in MFC-7 cells. EGFR/COX-2-IN-1 exhibits broad-spectrum antitumor effects .

HY-157399

EGFR/HER2-IN-10	EGFR	Cancer
EGFR/HER2-IN-10 (compound 9F) is a potent and selective dual *EGFR/HER2* inhibitor with IC₅₀s of 2.3 nM and 234 nM for EGFR and HER2, respectively. EGFR/HER2-IN-10 shows an effective antiproliferative action against prostate carcinoma .

HY-174841

EGFR/HER2-IN-19	EGFR	Cancer
EGFR/HER2-IN-19 (Compound L1) is a dual inhibitor against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-19 is promising for research of cancers driven by EGFR/HER2 .

HY-151158

EGFR/HER2-IN-7	EGFR	Cancer
EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2-IN-7 is a *EGFR/HER2* kinase and DHFR inhibitor, with IC₅₀s of 0.18 μM (EGFR), 0.146 μM (HER2), respectively. EGFR/HER2-IN-7 shows moderate inhibition on DHFR (IC₅₀=0.907 μM) .

HY-179140

EGFR/VEGFR2-IN-8	EGFR VEGFR Apoptosis	Cancer
EGFR/VEGFR2-IN-8 (compound 10k) is a dual *EGFR/VEGFR-2* inhibitor (EGFR IC₅₀ = 57 nM, VEGFR-2 IC₅₀ = 21 nM). EGFR/VEGFR2-IN-8 has anti proliferative activity against various tumor cells, such as MCF-7 (IC₅₀ = 20 nM), Panc-1 (IC₅₀ = 22 nM), A-549 (IC₅₀ = 23 nM), HT-29 (IC₅₀ = 23 nM) cells. EGFR/VEGFR2-IN-8 has antioxidant and apoptosis inducing activity. EGFR/VEGFR2-IN-8 can be used for research on various types of cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of *EGFR, HER2*, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

Cat. No.	Product Name	Chemical Structure

HY-13272S3

Dacomitinib-d10
Dacomitinib-d₁₀ is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .

HY-13272S2

Dacomitinib-d10 dihydrochloride
Dacomitinib-d₁₀ dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .

Cat. No.	Product Name		Classification

HY-159519

EGFR/HER2-IN-16		Azide
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of *EGFR* (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HY-15661A

OSI-413 free base CP 373413		Alkynes
OSI-413 (free base) (CP 373413) is a major metabolite of Erlotinib (HY-50896). Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR .

Cat. No.	Product Name		Classification

HY-174671

Human HBEGF mRNA		mRNA
Human HBEGF mRNA encodes the human heparin binding EGF like growth factor (HBEGF) protein, a growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. HBEGF may be involved in normal cardiac valve formation and normal heart function.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: